POLYNUCLEOTIDE COMPOSITIONS FOR THE TREATMENT OF PREMATURE TERMINATION DISEASES
Polynucleotide compositions comprising (a) a complementary oligonucleotide comprising at least 10 consecutive nucleobases having at least 80% complementarity to a target gene having a premature UGA stop codon; (b) an optional linker selected from the group consisting of (i) an oligonucleotide and (i...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | AGARWAL, Anurag BADNER, Anna Maria BRACKEN, Racquel Noh POON, Yan Shuen COFFEY, Eliot Leo |
| description | Polynucleotide compositions comprising (a) a complementary oligonucleotide comprising at least 10 consecutive nucleobases having at least 80% complementarity to a target gene having a premature UGA stop codon; (b) an optional linker selected from the group consisting of (i) an oligonucleotide and (ii) a chemical linker; and (c) an oligonucleotide comprising a SECIS element, or pharmaceutically acceptable salts thereof are disclosed herein.
Les compositions polynucléotidiques comprennent (a) un oligonucléotide complémentaire comprenant au moins 10 nucléobases consécutives ayant au moins 80 % de complémentarité avec un gène cible ayant un codon d'arrêt UGA prématuré ; (b) un lieur facultatif choisi dans le groupe constitué par (i) un oligonucléotide et (ii) un lieur chimique ; et (c) un oligonucléotide comprenant un élément SECIS, ou des sels pharmaceutiquement acceptables de celui-ci. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023215321A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023215321A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023215321A33</originalsourceid><addsrcrecordid>eNqNikEKwjAQAHPxIOofFjwLmuADQrqhC002JFvEUykST6KF-n-s4AM8DAPDrBUn7q6xdx2yUIPgOCQuJMSxgOcM0iJIRisBowB7SBmDlT4vGXOgaL8vNFTQFixbtbqPj7nuft6ovUdx7aFOr6HO03irz_oeLqyP2ujTecEa89_1AV3oMEw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>POLYNUCLEOTIDE COMPOSITIONS FOR THE TREATMENT OF PREMATURE TERMINATION DISEASES</title><source>esp@cenet</source><creator>AGARWAL, Anurag ; BADNER, Anna Maria ; BRACKEN, Racquel Noh ; POON, Yan Shuen ; COFFEY, Eliot Leo</creator><creatorcontrib>AGARWAL, Anurag ; BADNER, Anna Maria ; BRACKEN, Racquel Noh ; POON, Yan Shuen ; COFFEY, Eliot Leo</creatorcontrib><description>Polynucleotide compositions comprising (a) a complementary oligonucleotide comprising at least 10 consecutive nucleobases having at least 80% complementarity to a target gene having a premature UGA stop codon; (b) an optional linker selected from the group consisting of (i) an oligonucleotide and (ii) a chemical linker; and (c) an oligonucleotide comprising a SECIS element, or pharmaceutically acceptable salts thereof are disclosed herein.
Les compositions polynucléotidiques comprennent (a) un oligonucléotide complémentaire comprenant au moins 10 nucléobases consécutives ayant au moins 80 % de complémentarité avec un gène cible ayant un codon d'arrêt UGA prématuré ; (b) un lieur facultatif choisi dans le groupe constitué par (i) un oligonucléotide et (ii) un lieur chimique ; et (c) un oligonucléotide comprenant un élément SECIS, ou des sels pharmaceutiquement acceptables de celui-ci.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS OR TEST PAPERS THEREFOR ; COMPOSITIONS THEREOF ; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROCESSES OF PREPARING SUCH COMPOSITIONS ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240516&DB=EPODOC&CC=WO&NR=2023215321A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240516&DB=EPODOC&CC=WO&NR=2023215321A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>AGARWAL, Anurag</creatorcontrib><creatorcontrib>BADNER, Anna Maria</creatorcontrib><creatorcontrib>BRACKEN, Racquel Noh</creatorcontrib><creatorcontrib>POON, Yan Shuen</creatorcontrib><creatorcontrib>COFFEY, Eliot Leo</creatorcontrib><title>POLYNUCLEOTIDE COMPOSITIONS FOR THE TREATMENT OF PREMATURE TERMINATION DISEASES</title><description>Polynucleotide compositions comprising (a) a complementary oligonucleotide comprising at least 10 consecutive nucleobases having at least 80% complementarity to a target gene having a premature UGA stop codon; (b) an optional linker selected from the group consisting of (i) an oligonucleotide and (ii) a chemical linker; and (c) an oligonucleotide comprising a SECIS element, or pharmaceutically acceptable salts thereof are disclosed herein.
Les compositions polynucléotidiques comprennent (a) un oligonucléotide complémentaire comprenant au moins 10 nucléobases consécutives ayant au moins 80 % de complémentarité avec un gène cible ayant un codon d'arrêt UGA prématuré ; (b) un lieur facultatif choisi dans le groupe constitué par (i) un oligonucléotide et (ii) un lieur chimique ; et (c) un oligonucléotide comprenant un élément SECIS, ou des sels pharmaceutiquement acceptables de celui-ci.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS OR TEST PAPERS THEREFOR</subject><subject>COMPOSITIONS THEREOF</subject><subject>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROCESSES OF PREPARING SUCH COMPOSITIONS</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNikEKwjAQAHPxIOofFjwLmuADQrqhC002JFvEUykST6KF-n-s4AM8DAPDrBUn7q6xdx2yUIPgOCQuJMSxgOcM0iJIRisBowB7SBmDlT4vGXOgaL8vNFTQFixbtbqPj7nuft6ovUdx7aFOr6HO03irz_oeLqyP2ujTecEa89_1AV3oMEw</recordid><startdate>20240516</startdate><enddate>20240516</enddate><creator>AGARWAL, Anurag</creator><creator>BADNER, Anna Maria</creator><creator>BRACKEN, Racquel Noh</creator><creator>POON, Yan Shuen</creator><creator>COFFEY, Eliot Leo</creator><scope>EVB</scope></search><sort><creationdate>20240516</creationdate><title>POLYNUCLEOTIDE COMPOSITIONS FOR THE TREATMENT OF PREMATURE TERMINATION DISEASES</title><author>AGARWAL, Anurag ; BADNER, Anna Maria ; BRACKEN, Racquel Noh ; POON, Yan Shuen ; COFFEY, Eliot Leo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023215321A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2024</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS OR TEST PAPERS THEREFOR</topic><topic>COMPOSITIONS THEREOF</topic><topic>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROCESSES OF PREPARING SUCH COMPOSITIONS</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>AGARWAL, Anurag</creatorcontrib><creatorcontrib>BADNER, Anna Maria</creatorcontrib><creatorcontrib>BRACKEN, Racquel Noh</creatorcontrib><creatorcontrib>POON, Yan Shuen</creatorcontrib><creatorcontrib>COFFEY, Eliot Leo</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>AGARWAL, Anurag</au><au>BADNER, Anna Maria</au><au>BRACKEN, Racquel Noh</au><au>POON, Yan Shuen</au><au>COFFEY, Eliot Leo</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>POLYNUCLEOTIDE COMPOSITIONS FOR THE TREATMENT OF PREMATURE TERMINATION DISEASES</title><date>2024-05-16</date><risdate>2024</risdate><abstract>Polynucleotide compositions comprising (a) a complementary oligonucleotide comprising at least 10 consecutive nucleobases having at least 80% complementarity to a target gene having a premature UGA stop codon; (b) an optional linker selected from the group consisting of (i) an oligonucleotide and (ii) a chemical linker; and (c) an oligonucleotide comprising a SECIS element, or pharmaceutically acceptable salts thereof are disclosed herein.
Les compositions polynucléotidiques comprennent (a) un oligonucléotide complémentaire comprenant au moins 10 nucléobases consécutives ayant au moins 80 % de complémentarité avec un gène cible ayant un codon d'arrêt UGA prématuré ; (b) un lieur facultatif choisi dans le groupe constitué par (i) un oligonucléotide et (ii) un lieur chimique ; et (c) un oligonucléotide comprenant un élément SECIS, ou des sels pharmaceutiquement acceptables de celui-ci.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2023215321A3 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE |
| title | POLYNUCLEOTIDE COMPOSITIONS FOR THE TREATMENT OF PREMATURE TERMINATION DISEASES |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T22%3A24%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=AGARWAL,%20Anurag&rft.date=2024-05-16&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023215321A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |